Evidence map›Paper›PMID 35666590›Full record

ArticleJournal of the Chinese Medical Association : JCMA2022

The study of cancer cell in stromal environment through induced pluripotent stem cell-derived mesenchymal stem cells.

Jit-Kai Loh, Mong-Lien Wang, Soon-Keng Cheong, Fu-Ting Tsai, Shu-Huei Huang, Jing-Rong Wu, Yi-Ping Yang, Shih-Hwa Chiou, Alan Han-Kiat Ong

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Chinese Medical Association : JCMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Jit-Kai LohInstitute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Mong-Lien WangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Soon-Keng CheongFaculty of Medicine and Health Sciences, Universitiy Tunku Abdul Rahman, Cheras, Malaysia.
Fu-Ting TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Shu-Huei HuangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Jing-Rong WuDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yi-Ping YangInstitute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Shih-Hwa ChiouInstitute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Alan Han-Kiat OngFaculty of Medicine and Health Sciences, Universitiy Tunku Abdul Rahman, Cheras, Malaysia.
Taipei Veterans General Hospital · TWUniversiti Tunku Abdul Rahman · MYChinese Medical Association · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of mesenchymal stem cells (MSCs) has gained reputation from its therapeutic potential in stem cell regeneration, anti-inflammation, tumor suppression, and drug delivery treatment. Previous studies have shown MSCs have both promoting and suppressing effects against cancer cells. While the limitation of obtaining a large quantity of homologous MSCs for studies and treatment remains a challenge, an alternative approach involving the production of MSCs derived from induced pluripotent stem cells (iPSCs; induced MSCs [iMSCs]) may be a promising prospect given its ability to undergo prolonged passage and with similar therapeutic profiles as that of their MSC counterparts. However, the influence of iMSC in the interaction of cancer cells remains to be explored as such studies are not well established. In this study, we aim to differentiate iPSCs into MSC-like cells as a potential substitute for adult MSCs and evaluate its effect on non-small-cell lung cancer (NSCLC).

methodsiMSCs were derived from iPSCs and validated with reference to the International Society of Cellular Therapy guidelines on MSC criteria. To create a stromal environment, the conditioned medium (CM) of iMSCs was harvested and applied for coculturing of NSCLC of H1975 at different concentrations. The H1975 was then harvested for RNA extraction and subjected to next-generation sequencing (NGS) for analysis.

resultsThe morphology of iMSCs-CM-treated H1975 was different from an untreated H1975. Our NGS data suggest the occurrence of apoptotic events and the presence of cytokines from H1975's RNA that are treated with iMSCs-CM.

conclusionOur results have shown that iMSCs may suppress the growth of H1975 by releasing proapoptotic cytokines into coculture media. Using iPSC-derived MSC models allows a deeper study of tumor cross talk between MSC and cancer cells that can be applied for potential future cancer therapy.

Indexed as

Carcinoma, Non-Small-Cell LungInduced Pluripotent Stem CellsLung NeoplasmsMesenchymal Stem CellsCell DifferentiationCytokinesHumansRNACytokinesRNA

Identifiers

PMID35666590
PMCPMC12755493
OpenAlexW4282935347

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.